After laparotomy, treating large incisional hernias (width >= 10cm) proves challenging due to the progressive retraction of lateral abdominal muscles and the separation of rectus muscles. This width is a significant risk factor for repair failure and recurrence. High rates of severe postoperative morbidity, up to 50%, are reported, linked to dissection extent, increased muscular tension, and abdominal pressure. Reconstructing normal anatomy by bringing muscles together may be impossible, leading to the use of complex procedures like component separation techniques (CST), involving large aponeurotomy for muscle relaxation. Intramuscular injection of botulinum toxin A (BTA) induces reversible flaccid paralysis, with potential benefits in hernia closure, known as "chemical CST." Retrospective studies suggest reduced muscle retraction and facilitated closure without specific morbidity. Prehabilitation with BTA aims to reduce surgical morbidity compared to repair and CST. The prospective evaluation of BTA's clinical benefits, including reduced postoperative morbidity, pain, successful abdominal closure, and decreased IH recurrence risk, is lacking. A prospective randomized double-blind placebo-controlled trial is proposed to demonstrate BTA's efficacy. The hypothesis is that BTA injection before IH repair is more effective than a placebo in reducing postoperative morbimortality. Secondary expectations include a significant reduction in complete closure of the abdominal wall without CST.

Start Date17 Jan 2025

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT06604832

/ RecruitingPhase 1IIT

Effects of PrabotulinumtoxinA-xvfs on Facial Skin Quality, Fine Wrinkles, and Texture

The goal of this split-face clinical trial is to test the efficacy of microtox in improving facial skin quality, fine wrinkles, and texture. Participants will:
* be randomly assigned to Group A (which will receive 20 units of neuromodulator on the left side of the forehead and a placebo saline treatment on the right side) or Group B (which will receive 20 units of neuromodulator on the left side of the forehead and 20 units of a different neuromodulator brand on the right side as a comparator)
* have one treatment session at week 0, and two live assessment visits at weeks 2 and 12
* have their pictures taken at each visit to track progress

Start Date03 Sep 2024

Sponsor / Collaborator

Evolus, Inc.

NCT06788158

/ Active, not recruitingPhase 1IIT

Clinical Effects of the Intralesional Application of Incobotulinum Toxin vs Corticosteroid in Patients With Plantar Fascitis

Objectives: To evaluate the clinical effects of intralesional application of incobotulinum toxin vs corticosteroid in patients with plantar fasciitis .
Material and methods: Prospective, experimental, randomized, controlled clinical study; the population will be recruited in the outpatient clinic of the rehabilitation service meeting the inclusion criteria, two randomized study groups will be formed: GROUP A: Patients who accept intralesional infiltration with incobotulinum toxin . GROUP B: Patients who accept intralesional infiltration with dexamethasone.
Both groups will be assessed before application, at 1 month, at 2 and 4 months post intervention. The visual analogue scale (VAS), the American Orthopaedic Foot and Ankle Society (AOFAS) scale and the Foot and Ankle Disability Index (FADI) will be used to assess pain, foot functionality, functional disability index in activities of daily living, in physical activity and measurement of the dorsiflexion arch in 2 visits at the beginning of diagnosis and at 4 months, collecting the variables and establishing a hypothesis analysis to accept or discard normality criteria of the same with tendency and its significance in relation to p <0.05 to establish contrast of the results with parametric or non-parametric variables according to whether or not the hypothesis of normality is discarded.

Start Date01 Sep 2024

Sponsor / Collaborator

Instituto Mexicano del Seguro Social

100 Clinical Results associated with Incobotulinum toxinA (Biotecon)

100 Translational Medicine associated with Incobotulinum toxinA (Biotecon)

100 Patents (Medical) associated with Incobotulinum toxinA (Biotecon)

897

Literatures (Medical) associated with Incobotulinum toxinA (Biotecon)

01 Dec 2025·Techniques in Coloproctology

Urge fecal incontinence: are intramural rectal injections of botulinum toxin a long-term treatment option?

Article

Author: Baumstarck, Karine ; Vitton, Véronique ; Onana Ndong, Philippe

BACKGROUND AND AIMS:

Unsuccessful first-line conservative treatments for managing fecal incontinence (FI) lead to considering predominantly invasive options, posing challenges in terms of cost and patient acceptance of benefit/risk ratio. Recent data from a prospective randomized study have highlighted intramural rectal botulinum toxin (BoNT/A) injection as a promising minimally invasive alternative for urge FI, demonstrating efficacy at 3 months but lacking long-term evidence. This study aimed to evaluate the sustained efficacy and injection frequency of intramural rectal BoNT/A injection in the treatment of urge FI.

METHODS:

This retrospective monocentric study enrolled all patients who underwent intramural rectal BoNT/A injection for urge FI after failed conservative therapy or sacral neuromodulation (SNM). Injections were administered during sigmoidoscopy, delivering 200 U of BoNT/A at 10 circumferentially distributed sites. Treatment effectiveness was assessed using the Cleveland clinic incontinence score (CCS) and a visual analog scale (VAS) to measure the severity of discomfort related to episodes of fecal urgency, with reinjection performed upon symptom recurrence.

RESULTS:

In total, 41 patients (34 females) were included, with a median follow-up of 24.9 (range 3.2-70.3) months. Overall, 11 patients had previously failed sacral nerve stimulation. Significant reductions were observed in the CCS (median 11 versus 7, p = 0.001) and VAS symptoms (median 4, range 0-5 versus median 2, range 0-5, p = 0.001). In total, 22 patients (53%) experienced a reduction in the CCS by over 50%. The median interval between intramural rectal BoNT/A injections was 9.8 months (range 5.3-47.9 months).

CONCLUSIONS:

This study provides the first evidence of the sustained efficacy of intramural rectal BoNT/A injection for urge FI. Further investigations are warranted to refine patient selection and reinjection criteria, evaluate socioeconomic impacts, and compare rectal BoNT/A injection with other therapeutic modalities.

01 Mar 2025·JOURNAL OF STRUCTURAL BIOLOGY

Inter-Domain interactions Slow BoNT/A’s onset of action

Article

Author: Lalaurie, C J ; Zloh, M ; Bunting, K A ; Higazi, D R ; Dalby, P A

Despite sharing ∼ 43 % sequence identity and structurally similar individual domains, botulinum neurotoxin (BoNT) serotypes A and E have differences in their properties and domain positioning. BoNT/E has a faster onset of action than BoNT/A. This difference is proposed to be due to conformational differences between BoNT/E and the other BoNT serotypes. Where most serotypes have the light chain (LC) and binding domain (BD) on opposite sides of the translocation domain (TD), BoNT/E forms a more compact shape with direct interactions between residues of the LC and BD. To elucidate the structural basis for the different properties of BoNT/A and BoNT/E, biophysical studies including molecular dynamic (MD) simulations, circular dichroism (CD) and small-angle X-ray scattering (SAXS) were applied to BoNT/A, for comparison against previous work on BoNT/E. MD simulationsat six pH values across the toxin's activation barrier (pH ∼ 5.5), followed by one extra repeat for the pH values below 5.5, revealed a rare event at pH 5 and 5.5 where interactions between a previously identified switch region of BoNT/Aand the BD were lost.This hintedat an increased freedom of movement, thus allowing the region to change from α-helical to a β-hairpin. In good agreement with previous work, CD showed a gradual and small loss of helicity as the pH decreased below pH 5.5, stabilising at pH 4.5. Combined with the relative scarcity of structural changes observed by MD in the switch region required for activity, these results may explain the slower onset of action for BoNT/A compared to BoNT/E.

18 Feb 2025·Aesthetic Surgery Journal

IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies

Article

Author: Mersmann, Sabine ; Sudimac, Vladimir ; Joseph, John ; Kerscher, Martina

Abstract:

Background:

Two randomized, double-blind, placebo-controlled, Phase III studies of incobotulinumtoxinA for treating upper facial lines (UFLs; ie, a combination of glabellar frown lines [GFLs], horizontal forehead lines [HFLs], and lateral canthal lines [LCLs]) were conducted in the United States (ULTRA I: NCT04594213) and Germany (ULTRA II: NCT04622254).

Objectives:

The aim of this study was to evaluate the safety and efficacy of simultaneous intramuscular injections for UFLs. Longer-term safety and efficacy were assessed in open-label extension periods.

Methods:

Healthy participants (≥18 years) with moderate-to-severe GFLs, HFLs, and symmetric LCLs at maximum contraction on the 5-point Merz Aesthetics Scales were randomized 2:1:1 to receive up to 64 units of incobotulinumtoxinA in the main period for each trial. Treatment groups were: UFLs, GFLs, and HFLs (ULTRA I), LCLs (ULTRA II), and placebo. Primary efficacy endpoints were the proportions of GFL, HFL, and LCL responders, defined as a Merz Aesthetics Scale score for the respective area of 0 (no) or 1 (mild) and a ≥2-grade improvement from baseline to Day 30, as assessed by both investigator and participant.

Results:

Overall, 362 and 368 participants received treatment in ULTRA I and ULTRA II, respectively. In both studies, incobotulinumtoxinA treatment was significantly more effective than placebo with respect to the primary endpoints (P < .0001) and key secondary endpoints (P < .0001). The open-label extension period results were consistent with those seen in the main period. No new safety findings were identified.

Conclusions:

In ULTRA I and ULTRA II, the safety and efficacy of incobotulinumtoxinA for the simultaneous treatment of moderate-to-severe UFLs were demonstrated, with significant improvements across all primary and secondary endpoints vs placebo.

Level of Evidence: 1 (Therapeutic):

News (Medical) associated with Incobotulinum toxinA (Biotecon)

18 Dec 2024

·www.prnewswire.com

Persimmon.life Introduces SmartTox® Injectable Treatment Offered at Select Massage Envy Locations

Persimmon.life will provide their medical aesthetic services at select Massage Envy Franchised locations across Arizona and California in early 2025 SCOTTSDALE, Ariz., Dec. 18, 2024 /PRNewswire/ -- Massage Envy, a national leader in skin care and the nation's No. 1 provider of massage in the U.S. collectively across its franchise network, and Persimmon.life, the leader in on-location medical aesthetic treatments, today announced a new initiative in which Persimmon will offer SmartTox® injectable treatments at select Massage Envy franchised locations across Arizona and California in early 2025. "Massage Envy is always looking for strategic relationships with brands that help address consumers' wellness goals. Persimmon's use of Massage Envy locations to provide their medical aesthetic services will not only be convenient, but will also address the needs of the modern skincare consumer," said Todd Schrader, CEO, Massage Envy Franchising. "Massage Envy has been a leader in skin care for over 16 years and looking and feeling your best is at the core of the Massage Envy brand. We are excited that our franchisees are welcoming Persimmon into their Massage Envy franchised locations." Each Persimmon service includes a personalized assessment with a Persimmon Provider, who will review goals, answer questions and explain the treatment. Sessions typically take between 15 and 20 minutes. "Massage Envy is a company that has set the standard for accessible wellness and self-care," said Mark Hadfield, CEO, Persimmon.life. "At Persimmon, we share Massage Envy's commitment to helping people look and feel their best, and we're thrilled that Persimmon will be on-site at select Massage Envy franchised locations to provide high-quality, medically-driven SmartTox® treatments." According to Persimmon.life, SmartTox®, also known as XEOMIN® and IncobotulinumtoxinA or Neurotoxin, is a double-filtered neuromodulator injection that smooths upper facial lines including frown lines, forehead lines and crow's feet without unnecessary proteins. The procedure will be available by appointment only at select Massage Envy California and Arizona franchise locations beginning in early 2025. For more information and to make an appointment, visit the Persimmon website at . About Persimmon Founded in 2021, Persimmon is at the forefront of medical aesthetics, transforming how aesthetic treatments are provided. By partnering with local businesses, Persimmon offers clients unparalleled flexibility and privacy through a growing network of highly skilled, medically-trained injection nurses available at select partnership locations. Guided by a clinical leadership team of expert nurses, Persimmon has established itself as a leader in safety, quality, and care. Their meticulously-designed training and treatment protocols ensure every client experiences top-tier results. With thousands of glowing five-star reviews, Persimmon's reputation speaks to its commitment to excellence and its ability to deliver transformative care in a setting that clients trust and enjoy. For more information, visit or follow @persimmon.life on Instagram, TikTok and Facebook. About Massage Envy Massage Envy, based in Scottsdale, Arizona, is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services and skin care offerings. Massage Envy was founded in 2002 and started offering skin care services in 2008. The brand now has over 1,000 franchise locations in 49 states that have together delivered more than 225 million massages and skin care services. For more information, visit or follow @MassageEnvy on Instagram, X and Facebook. Contact: [email protected] SOURCE Massage Envy WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Dec 2024

·www.businesswire.com

Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot

BURLINGTON, Ontario--( BUSINESS WIRE )-- Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ® (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults. “This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option,” explains Michael Stone, Country Manager, Canada for Merz Therapeutics. “With this label extension, healthcare providers can now utilize XEOMIN to pursue more comprehensive and individually ambitious treatment goals for their patients.” Addressing multiple patterns of spasticity with XEOMIN Strokes are the primary cause of spasticity resulting from damage to the upper motor neuron, producing an abnormal increase in muscle tone. In Canada, 109,000 people annually suffer a stroke 1 , and 25% to 43% of stroke survivors experience spasticity within a year 2 . XEOMIN with the active ingredient incobotulinumtoxinA is injected intramuscularly to reduce the abnormally increased muscle tone. With the new approval, XEOMIN can be administered in up to 600 units for upper and lower limbs combined, enabling qualified healthcare professionals in Canada to treat both regions together or individually, adjusting the dosage depending on patient requirements and mobility goals. The safety findings were similar to previous adult studies and in line with the known safety profile of XEOMIN. The most common adverse reactions affecting ≥1% of patients were nasopharyngitis, pharyngitis, tinea pedis, muscular weakness, epilepsy, fall, eczema, dehydration, and blurred vision. “Foot and ankle spasticity are the most common posture problems seen in the lower limb in adult patients following a stroke. They typically present with an equinovarus deformity, which refers to the foot turning downwards and inwards in these limbs," said Professor Lalith Satkunam, Glenrose Rehabilitation Hospital, Edmonton, Alberta. "Lower limb spasticity can limit ambulation and impede on patients' daily lives, so this latest approval for XEOMIN provides healthcare professionals, like me, the ability to comprehensively treat multiple areas of spasticity.” “The ability to simultaneously treat both upper and lower limb post-stroke spasticity in adults with botulinum toxin using a combined total dose of 600 units makes it an essential tool in our treatment arsenal,” shared Dr. Jehane Dagher, Institut de réadaptation Gingras-Lindsay-de-Montréal (IRGLM), Montreal, Quebec. A label extension built on solid data Canada is the third country to authorize XEOMIN for lower limb treatment based on data from a Japanese study (J-PLUS), which investigated the effects of XEOMIN on spasticity in Japanese stroke survivors. “Health Canada’s decision to extend XEOMIN’s area of application once again underlines the quality and robustness of our Japanese data and is a testament to our conviction that delivering better outcomes for more patients must be an international effort,” says Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “We were able to extrapolate the clinical data generated in Japan to support the application with Health Canada based on a larger dataset from multiple clinical trials and decisive efficacy data from a Japanese study.” Previously, data from J-PLUS had also been included in application packages for label extensions for lower limb treatment in the United Kingdom and Switzerland. This is the sixth therapeutic indication for XEOMIN in Canada, which was first licensed by Health Canada in 2009 for the treatment hypertonicity disorders of the seventh nerve such as blepharospasm, including benign essential blepharospasm and hemifacial spasm in adults, to reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults, and for the treatment of upper limb spasticity in adults. 3 XEOMIN was also licensed for adult patients with chronic sialorrhea in 2020 and for pediatric patients (age 2-17 years weighing 12 kg or more) in 2022. References 1. Holodinsky JK, Lindsay P, Yu AYX, Ganesh A, Joundi RA, Hill MD. Estimating the Number of Hospital or Emergency Department Presentations for Stroke in Canada. Can J Neurol Sci . 2023;50(6):820-825. doi:10.1017/cjn.2022.338 2. Effects of Stroke, Phyiscal Effects, Spasticity . 30 May 2023, www.stroke.org/en/about-stroke/effects-of-stroke/physical-effects/spasticity . Accessed 4 Nov. 2024. 3. XEOMIN ® Product Monograph. Merz Pharma Canada Ltd. December 11, 2024. About XEOMIN ® XEOMIN ® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles or glands and used to treat adults and pediatric patients with chronic drooling (sialorrhea), eyelid spasm (blepharospasm) and spasm in one side of the face (hemifacial spasm), twisted neck (spasmodic torticollis), spasticity of the upper limb in adults and post-stroke lower limb spasticity involving the ankle and foot in adults. Copyright © 2024 Merz Pharma Canada Ltd. All rights reserved. MERZ, the MERZ logo, and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA. For more information, please see the XEOMIN ® full Product Monograph . About Merz Therapeutics Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a Canada affiliate based in Burlington, Ontario, Canada. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 116 years to developing innovations that serve unmet patient and customer needs. Please visit www.merztherapeutics.com About Merz Merz Group is a global, diversified company in the healthcare sector based in Frankfurt, Germany. Family-owned for over 116 years, the company is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 4,337 people (as of the 22/23 financial year) in 28 countries worldwide. To learn more, please visit www.merz.com .

Drug Approval

28 Oct 2024

·www.prnewswire.com

Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment

Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment BROOKLYN, N.Y., Oct. 28, 2024 /PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its revolutionary treatment of overactive bladder (OAB) using botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device. Continue Reading (from l-r) Avner Geva, Vensica Therapeutics CEO & Co Founder; Avi Eftel, Vensica Therapeutics CTO & Co Founder The investment round was led by Israel Biotech Fund (IBF), alongside key strategic partners, Merz, a global player in neurotoxins, and Laborie, a prominent urology medical device company. This funding will enable Vensica to continue its mission of providing a minimally invasive, simple, and effective solution for people with overactive bladder ("OAB"). Vensica's unique technology leverages a needle-free drug delivery system, that administers Xeomin® directly to the bladder wall. This approach is expected to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica's needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications. "We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment," remarked Avner Geva, CEO of Vensica. "This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it." As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic application in several urologic indications and will benefit from Merz's clinical development support. This collaboration marks a significant step forward in the company's goal of delivering next-generation urology treatments. For more information on Vensica and its upcoming clinical trials, visit . About Vensica Medical Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder in a minimally invasive manner. Vensica was established in the incubator program of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority. Contact: Avner Geva, Chief Executive Officer [email protected] Photo: SOURCE Vensica Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

100 Deals associated with Incobotulinum toxinA (Biotecon)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Incobotulinum toxinA (Biotecon)	M03AX01	DB00083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
cervical dystonia	AU	Merz Australia Pty Ltd	28 Nov 2023
Crow's feet	AU	Merz Australia Pty Ltd	28 Nov 2023
Forehead lines	AU	Merz Australia Pty Ltd	28 Nov 2023
Lower limb spasticity	JP	Teijin Pharma Ltd.	29 Jun 2020
Upper limb spasticity	JP	Teijin Pharma Ltd.	29 Jun 2020
Limb spasticity	US	Merz Pharmaceuticals LLC	22 Dec 2015
Glabellar frown lines	US	Merz Pharmaceuticals LLC	20 Jul 2011
Blepharospasm	US	Merz Pharmaceuticals LLC	30 Jul 2010
Torticollis	US	Merz Pharmaceuticals LLC	30 Jul 2010
Sialorrhea	DE	Merz Pharmaceuticals GmbH	24 Oct 2007
Spasm	DE	Merz Pharmaceuticals GmbH	24 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrial Fibrillation	Phase 3	FR	Merz Pharmaceuticals GmbH	30 Sep 2019
Intellectual Disability	Phase 3	GE	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	HU	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	PL	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	RU	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	RS	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	UA	Merz Pharmaceuticals GmbH	09 Feb 2015
Brain Injuries, Traumatic	Phase 3	DE	Merz Pharmaceuticals GmbH	01 Apr 2014
Brain Injuries, Traumatic	Phase 3	PL	Merz Pharmaceuticals GmbH	01 Apr 2014
Parkinson Disease	Phase 3	DE	Merz Pharmaceuticals GmbH	01 Apr 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04622254 (ULTRA II, CTgov)	Phase 3	-	368	Placebo (Main Period: Placebo (Group P))	apclazkzvi(kyruwmzcle) = okrssveylh fqrqijrnqf (mphkfntrlk, nquewxwsbg - dohdodljig) View more	-	06 Aug 2024
				NT 201 (Main Period: NT 201 (Group U))	apclazkzvi(kyruwmzcle) = jgbrfqnxxs fqrqijrnqf (mphkfntrlk, appkhufpcz - peabkltwqh) View more
NCT04594213 (ULTRA I, CTgov)	Phase 3	-	362	Placebo (Main Period: Placebo (Group P))	lztztnpsky(ffsiuosbmo) = qzdjfvlyzs jwzgglcgii (nvqbbxrunj, bqtausjkxk - fxwthmbjqj) View more	-	08 May 2024
				NT 201 (Main Period: NT 201 (Group U))	lztztnpsky(ffsiuosbmo) = bblirljbre jwzgglcgii (nvqbbxrunj, qpnpdrezpg - ljczfocjxw) View more
P8-3.004 (AAN2024)	Not Applicable	cervical dystonia	451	IncobotulinumtoxinA	yxrexahdul(irfidpxmga) = dwsvizjqua icbbiefial (qzifjhxzut ) View more	Positive	09 Apr 2024
				Placebo	yxrexahdul(irfidpxmga) = jiepkoplos icbbiefial (qzifjhxzut ) View more
NCT03806933 (CTgov)	Phase 2	-	241	MP+NT 201 (Stage 1 and 2 Pooled: NT 201 20 U)	detbwkbgjl(ezppliynaj) = yvnrgdijcu zgvwipcovk (bgthjhtrwf, plidhwbanq - uwfjdondlt) View more	-	04 Oct 2023
				MP+NT 201 (NT 201 50 U)	detbwkbgjl(ezppliynaj) = sdpbsarezy zgvwipcovk (bgthjhtrwf, tbztsbwzbo - rgcjhsiehx) View more
MDS2023	Not Applicable	-	451	IncobotulinumtoxinA	yedmtmlduj(xiyekajuza) = yrjtoxdgib wodmmfvpzo (myitbsbpxa )	-	27 Aug 2023
				Placebo	yedmtmlduj(xiyekajuza) = pqcrimrmaf wodmmfvpzo (myitbsbpxa )
NCT02088632 (CTgov)	Phase 2	Trigeminal Neuralgia	6	Incobotulinumtoxina (Incobotulinumtoxina)	hzzxpiggzv(lgpfzouclo) = bortslrcuo kykbubzxwg (bazbzhktki, xrsjoqlyhu - aglswensxk) View more	-	28 Jun 2023
				Placebo Comparator (Placebo Comparator)	hzzxpiggzv(lgpfzouclo) = kbuubmbnpd kykbubzxwg (bazbzhktki, zmkyaoebeo - abevmdrstn) View more
P14-11.008 (AAN2023)	Phase 2/3	Limb spasticity	542	IncobotulinumtoxinA	ixwsxmgigm(rvkbibhitx) = hhfwdmalan fqezhrazal (blejkrvyiw ) View more	Positive	25 Apr 2023
				Placebo	ixwsxmgigm(rvkbibhitx) = zhbarqrmbo fqezhrazal (blejkrvyiw ) View more
P12-11.009 (AAN2023)	Phase 2/3	Limb spasticity	515	incoA injections	vvxhtjiwkj(csjjakcrst) = wwshpqdbpr xtzzgzhgrq (mawkijcqbl ) View more	-	25 Apr 2023
NCT04148872 (CTgov)	Phase 4	Facial Paralysis \| Synkinesis	15	Neuromuscular Retraining + Chemodenervation (Neuromuscular Retraining Therapy)	ohwdzosvnj(zciljfslri) = gafbfaruqo wsgtibbhpl (bfnkyoansb, vipcsbzbma - fxdyrxmslx) View more	-	29 Sep 2022
				Chemodenervation (4 months) (Chemodenervation)	ohwdzosvnj(zciljfslri) = ootmrqajwp wsgtibbhpl (bfnkyoansb, kzgpxqraxk - veoqfarvxn) View more
MDS2022	Phase 2/3	Limb spasticity	542	IncobotulinumtoxinA	jznrhbtjsj(xgpbqlcnmf) = ulmrsrpohx lvmeeolpim (nhtuviavwh ) View more	Positive	15 Sep 2022
				Placebo	jznrhbtjsj(xgpbqlcnmf) = epceyiszwv lvmeeolpim (nhtuviavwh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis